Literature DB >> 22881865

Metallofullerene-nanoplatform-delivered interstitial brachytherapy improved survival in a murine model of glioblastoma multiforme.

John D Wilson1, William C Broaddus, Harry C Dorn, Panos P Fatouros, Charles E Chalfant, Michael D Shultz.   

Abstract

Fullerenes are used across scientific disciplines because of their diverse properties gained by altering encapsulated or surface-bound components. In this study, the recently developed theranostic agent based on a radiolabeled functionalized metallofullerene ((177)Lu-DOTA-f-Gd(3)N@C(80)) was synthesized with high radiochemical yield and purity. The efficacy of this agent was demonstrated in two orthotopic xenograft brain tumor models of glioblastoma multiforme (GBM). A dose-dependent improvement in survival was also shown. The in vivo stability of the agent was verified through dual label measurements of biological elimination from the tumor. Overall, these results provide evidence that nanomaterial platforms can be used to deliver effective interstitial brachytherapy.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22881865      PMCID： PMC3448337          DOI： 10.1021/bc300206q

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN： 1043-1802            Impact factor:   4.774


  38 in total

1.  Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.

Authors:  Caterina Giannini; Jann N Sarkaria; Atsushi Saito; Joon H Uhm; Evanthia Galanis; Brett L Carlson; Mark A Schroeder; C David James
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

Review 2.  Fullerenes: from carbon to nanomedicine.

Authors:  Pooja Chawla; Viney Chawla; Radhika Maheshwari; Shubhini A Saraf; Shailendra K Saraf
Journal:  Mini Rev Med Chem       Date:  2010-07       Impact factor: 3.862

3.  Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.

Authors:  Stuart A Grossman; Xiaobu Ye; Steven Piantadosi; Serena Desideri; Louis B Nabors; Myrna Rosenfeld; Joy Fisher
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

4.  [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells.

Authors:  Mikael Persson; Vladimir Tolmachev; Karl Andersson; Lars Gedda; Mattias Sandström; Jörgen Carlsson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-29       Impact factor: 9.236

5.  Recurrent high-grade glioma.

Authors:  Eudocia C Quant; Jan Drappatz; Patrick Y Wen; Andrew D Norden
Journal:  Curr Treat Options Neurol       Date:  2010-07       Impact factor: 3.598

6.  Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis.

Authors:  Yi-Ping Yang; Yuh-Lih Chang; Pin-I Huang; Guang-Yuh Chiou; Ling-Ming Tseng; Shih-Hwa Chiou; Ming-Hsiung Chen; Ming-Teh Chen; Yang-Hsin Shih; Chin-Hong Chang; Chuan-Chih Hsu; Hsin-I Ma; Chin-Tien Wang; Lo-Lin Tsai; Cheng-Chia Yu; Charn-Jung Chang
Journal:  J Cell Physiol       Date:  2012-03       Impact factor: 6.384

7.  Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma.

Authors:  N J Laperriere; P M Leung; S McKenzie; M Milosevic; S Wong; J Glen; M Pintilie; M Bernstein
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-07-15       Impact factor: 7.038

Review 8.  Biomedical applications of functionalized fullerene-based nanomaterials.

Authors:  Ranga Partha; Jodie L Conyers
Journal:  Int J Nanomedicine       Date:  2009

9.  The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine.

Authors:  Robert G Selker; William R Shapiro; Peter Burger; Margaret S Blackwood; Vincent C Arena; John C Gilder; Mark G Malkin; John J Mealey; John H Neal; Jeffrey Olson; James T Robertson; Gene H Barnett; Stephen Bloomfield; Robert Albright; Fred H Hochberg; Emile Hiesiger; Sylvan Green
Journal:  Neurosurgery       Date:  2002-08       Impact factor: 4.654

Review 10.  Convection-enhanced delivery of nanocarriers for the treatment of brain tumors.

Authors:  Emilie Allard; Catherine Passirani; Jean-Pierre Benoit
Journal:  Biomaterials       Date:  2009-01-24       Impact factor: 12.479
View more
  6 in total

Review 1.  Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry.

Authors:  Su-Tang Lo; Amit Kumar; Jer-Tsong Hsieh; Xiankai Sun
Journal:  Mol Pharm       Date:  2013-01-24       Impact factor: 4.939

Review 2.  Nanomedicine in the application of uveal melanoma.

Authors:  Shuo You; Jing Luo; Hans E Grossniklaus; Ma-Ling Gou; Ke Meng; Qing Zhang
Journal:  Int J Ophthalmol       Date:  2016-08-18       Impact factor: 1.779

3.  Trimetallic Nitride Endohedral Fullerenes Carboxyl-Gd3N@C80: A New Theranostic Agent for Combating Oxidative Stress and Resolving Inflammation.

Authors:  Tinghui Li; Li Xiao; Jiezuan Yang; Mengmeng Ding; Zhiguo Zhou; Leslie LaConte; Li Jin; Harry C Dorn; Xudong Li
Journal:  ACS Appl Mater Interfaces       Date:  2017-05-19       Impact factor: 9.229

Review 4.  Synthetic nanoparticles for delivery of radioisotopes and radiosensitizers in cancer therapy.

Authors:  Jun Zhao; Min Zhou; Chun Li
Journal:  Cancer Nanotechnol       Date:  2016-11-16

5.  Modified Seed Growth of Iron Oxide Nanoparticles in Benzyl Alcohol - Optimization for Heating and Broad Stability in Biomedical Applications.

Authors:  Stanley E Gilliland; Everett E Carpenter; Michael D Shultz
Journal:  Nanobiomedicine (Rij)       Date:  2014-01-01

6.  Radiolabeled Gold Nanoseeds Decorated with Substance P Peptides: Synthesis, Characterization and In Vitro Evaluation in Glioblastoma Cellular Models.

Authors:  Francisco Silva; Alice D'Onofrio; Carolina Mendes; Catarina Pinto; Ana Marques; Maria Paula Cabral Campello; Maria Cristina Oliveira; Paula Raposinho; Ana Belchior; Salvatore Di Maria; Fernanda Marques; Carla Cruz; Josué Carvalho; António Paulo
Journal:  Int J Mol Sci       Date:  2022-01-06       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.